Compare HRMY & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | FORTY |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2020 | 1998 |
| Metric | HRMY | FORTY |
|---|---|---|
| Price | $41.14 | $114.99 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $44.11 | N/A |
| AVG Volume (30 Days) | ★ 849.5K | 433.0 |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | ★ $22.37 | $36.65 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $102.01 |
| 52 Week High | $43.49 | $190.56 |
| Indicator | HRMY | FORTY |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 48.29 |
| Support Level | $40.92 | $109.49 |
| Resistance Level | $43.38 | $119.68 |
| Average True Range (ATR) | 1.21 | 1.67 |
| MACD | -0.27 | 0.09 |
| Stochastic Oscillator | 40.51 | 34.78 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.